Insulin News and Research

RSS

Insulin is a hormone that is needed to convert glucose, starches and other food into energy needed for daily life. Insulin allows cells to use glucose for fuel and is secreted by beta cells in the islets of Langerhans. The release of insulin from the pancreas is stimulated by increased blood glucose, vagal nerve stimulation, and other factors. Insulin is obtained from various animals and available in a variety of preparations. Commercial insulin preparations differ in a number of ways, including differences in the animal species from which they are obtained; their purity, concentration, and solubility; and the time of onset and duration of their biologic action. An oral hypoglycemic agent is not a form of insulin therapy.

Tet 1 protein helps stem cells renew themselves and stay pluripotent: Researchers

Take a skin cell from a patient with Type 1 diabetes. Strip out everything that made it a skin cell, then reprogram it to grow into a colony of pancreatic beta cells. Implant these into your patient and voilà! She's producing her own insulin like a pro.

19 Jul 2010

AMPK may regulate epigenetic mechanism: Research

AMP-activated protein kinase, or AMPK, is a master regulator protein of metabolism that is conserved from yeast to humans. When a cell is low on fuel, AMPK shuts down processes that use energy and turns on processes that produce energy.Biologists have been studying how AMPK works for several decades and know that once it is activated, AMPK turns on a large number of genes by passing the "make more energy" message through numerous signaling cascades in the cell. What was not known, until now, was that AMPK also works via an epigenetic mechanism to slow down or stop cell growth.

17 Jul 2010

Ingen files patent to produce new drug insulin thermos product

Ingen Technologies, Inc. (Pink Sheets:IGNT), an emerging medical device manufacturer developing innovative solutions for the respiratory market, with a new patented and proprietary medical product line targeting the $8B respiratory market, announced today that the company has also filed a U.S patent and will begin the required manufacturing processes to produce the new drug insulin thermos product.

17 Jul 2010

ArmaGen uses BBB molecular Trojan horse platform technology to create brain penetrating form of human EPO

Human erythropoietin (EPO) is a potent neuroprotective agent for multiple brain disorders, including stroke, brain and spinal cord injury, and Parkinson's disease. However, EPO drug development for the brain is limited, because EPO does not cross the blood-brain barrier (BBB). In acute stroke or brain injury, the BBB is intact in the early hours after the insult when neuroprotection is still possible. Therefore, large molecule biopharmaceuticals such as EPO must be re-engineered to enable BBB transport.

17 Jul 2010

Scientists discover gene mutation responsible for CDG

An international team of scientists, led by researchers at the University of California, San Diego School of Medicine, has discovered the gene mutation responsible for a condition in which eye and brain development is severely disrupted in affected infants.

16 Jul 2010

Proteinuria screening identifies risk for kidney disease progression

A morning urine test is superior to all other tests for detecting declining kidney performance in patients with diabetic kidney disease, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results suggest that clinicians should monitor kidney function by measuring the albumin:creatinine ratio from a first morning urine sample.

16 Jul 2010

Insulet gone live with Pilgrim's on-demand Corrective and Preventive Action management solution

Pilgrim Software, Inc., a world-leading provider of Enterprise Risk, Compliance and Quality Management (ERCQM) software solutions, today announced that Insulet Corporation, a Massachusetts-based medical device company, has gone live with Pilgrim's On-Demand "SaaS" delivery of its automated management solution for Corrective and Preventive Action (CAPA) management.

16 Jul 2010

ACTOS offers safety profile regarding risk of CV events in people with type 2 diabetes: Takeda

The U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee held a joint meeting primarily focused on reviewing the cardiovascular safety of rosiglitazone, as presented by the FDA and GlaxoSmithKline. Following this two day discussion, Takeda Pharmaceuticals North America, Inc. ("Takeda") underscores its position that ACTOS (pioglitazone HCl) offers an established safety profile regarding the risk of CV events in people living with type 2 diabetes.

16 Jul 2010

Scientists gather to discuss latest advances in Alzheimer's disease at AAICAD 2010

This week, nearly 4,000 scientists from around the world gathered to report and discuss the latest advances in research on treatments, risk factors, and diagnosis for the health epidemic of the 21st century – Alzheimer's disease – at the Alzheimer's Association's 2010 International Conference on Alzheimer's Disease in Honolulu.

15 Jul 2010

Access announces agreement to develop oral formulation of proprietary injectable drugs

Access Pharmaceuticals, Inc., announced today that it has entered into a pre-licensing feasibility agreement with a leading biotechnology company to develop an oral formulation of its currently-marketed, proprietary injectable drugs. Access will utilize its proprietary Cobalamin Oral Drug Delivery Technology to develop oral formulations of the drug for pre-clinical testing.

15 Jul 2010

Type 1 diabetes affects athletic performance, new study finds

A new study led by York University researchers finds that young athletes with Type 1 diabetes may experience a marked decrease in performance as a result of their blood sugar levels.

15 Jul 2010

Adolescents with good physical condition experience better appetite control, energy expenditure: Study

Adolescents of ages between 12 and 17, with a good physical condition and regular physical activity present increased levels of insulin and leptin, which are hormones involved in the development of diabetes, appetite control and energy expenditure. This was the conclusion drawn from a study recently conducted at the Department of Physiology of the University of Granada. Further, after thorough analysis of a number of scientific studies, they also concluded that physical activity and physical condition are negatively associated to adolescents' body fat.

15 Jul 2010

NASDAQ panel grants Generex's request for continued listing

Generex Biotechnology Corporation today announced its receipt of a decision by the NASDAQ Listing Qualifications Panel, which granted the Company's request for continued listing of the Company's common stock on The NASDAQ Stock Market on an interim basis, subject to certain conditions subsequent which are described in the Form 8-K Current Report filed by the Company with the Securities and Exchange Commission on EDGAR earlier today.

15 Jul 2010

Dementia varies among diabetic, non-diabetic patients: Research

Researchers from Mayo Clinic's Florida campus say that dementia in some diabetics appears to be caused often by vascular disease in the brain, and the dementia that develops in people without diabetes is more likely associated with deposition of the plaque seen in people with Alzheimer's disease

15 Jul 2010

Key protein in insulin signaling pathway adds insights into development, aging

What makes a bee grow up to be a queen? Scientists have long pondered this mystery. Now, researchers in the School of Life Sciences at Arizona State University have fit a new piece into the puzzle of bee development. Their work not only adds to understanding about bees, but also adds insights into our own development and aging.

15 Jul 2010

Study reveals anti-diabetic properties of cashew seed extract

Cashew seed extract shows promise as an effective anti-diabetic, according to a new study from the University of Montreal (Canada) and the Universit- de Yaound- (Cameroun). Published in the journal Molecular Nutrition & Food Research, the investigation analyzed the reputed health benefits of cashew tree products on diabetes, notably whether cashew extracts could improve the body's response to its own insulin.

15 Jul 2010

GSK confirms FDA advisory committees' vote to allow Avandia to remain on the market

GlaxoSmithKline confirmed today that a joint advisory committee to the U.S. Food and Drug Administration (FDA) voted to allow Avandia to remain on the market. Committee members voted for recommendations ranging from making no changes to the current label, to revising the label with additional warnings and restrictions to withdrawal from the U.S. market.

15 Jul 2010

Study links obesity to poorer memory, brain function in older women

The more an older woman weighs, the worse her memory, according to new research from Northwestern Medicine. The effect is more pronounced in women who carry excess weight around their hips, known as pear shapes, than women who carry it around their waists, called apple shapes.

15 Jul 2010

Evotec to acquire DeveloGen

Evotec AG today announced the signing of a definitive agreement to acquire DeveloGen, a biopharmaceutical company engaged in the discovery of novel therapeutic approaches for the treatment of metabolic and endocrine disorders, for up to €14m in shares plus performance-related deferred payments (earn-out).

15 Jul 2010

BioInvent reports net revenues of SEK 63.1M for January - June 2010 period

BioInvent reached an important milestone when the results of a phase II trial of TB-402 following orthopaedic surgery, were reported in May. The data showed that TB-402 is statistically better at preventing thrombosis than enoxaparin, the current standard treatment. Supported by these good results, BioInvent and the company's partner, ThromboGenics, will now prioritise securing a development partner for the programme to ensure that the necessary resources is in place to take the product candidate to the market.

14 Jul 2010

Insulin News and Research

Further Reading

Tet 1 protein helps stem cells renew themselves and stay pluripotent: Researchers

AMPK may regulate epigenetic mechanism: Research

Ingen files patent to produce new drug insulin thermos product

ArmaGen uses BBB molecular Trojan horse platform technology to create brain penetrating form of human EPO

Scientists discover gene mutation responsible for CDG

Proteinuria screening identifies risk for kidney disease progression

Insulet gone live with Pilgrim's on-demand Corrective and Preventive Action management solution

ACTOS offers safety profile regarding risk of CV events in people with type 2 diabetes: Takeda

Scientists gather to discuss latest advances in Alzheimer's disease at AAICAD 2010

Access announces agreement to develop oral formulation of proprietary injectable drugs

Type 1 diabetes affects athletic performance, new study finds

Adolescents with good physical condition experience better appetite control, energy expenditure: Study

NASDAQ panel grants Generex's request for continued listing

Dementia varies among diabetic, non-diabetic patients: Research

Key protein in insulin signaling pathway adds insights into development, aging

Study reveals anti-diabetic properties of cashew seed extract

GSK confirms FDA advisory committees' vote to allow Avandia to remain on the market

Study links obesity to poorer memory, brain function in older women

Evotec to acquire DeveloGen

BioInvent reports net revenues of SEK 63.1M for January - June 2010 period

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News